Evidence map›Paper›PMID 1521210›Full record

Trial reportCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne1992

Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group.

N R Sinclair

Open access · greenAbstract readClinical TrialMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 204 citations in OpenAlex.

  1. Steroid avoidance or withdrawal for kidney transplant recipients.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Pooled it
  3. Steroid avoidance or withdrawal for kidney transplant recipients.The Cochrane database of systematic reviews · 2016
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Long-term results of protocol kidney biopsy directing steroid withdrawal in simultaneous pancreas-kidney transplant patients.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2018
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Steroids in kidney transplant patients.Seminars in immunopathology · 2011
    Review
  17. Article
  18. Review
  19. Review
  20. Recent developments in kidney transplantation--a critical assessment.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2009
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

N R SinclairCanadian Centre for Transplant Studies, University Hospital, London, Ont.
University Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLow-dose prednisone given on alternate days as a steroid adjunct to cyclosporine therapy was investigated primarily for its influence on kidney graft and patient survival and, secondarily, on renal function and complications.

designMulticentre randomized double-blind clinical trial.

settingFourteen Canadian transplant centres. PATIENTS: A total of 523 patients with well-functioning renal transplants (cadaveric grafts or grafts from living related donors) and without active graft rejection reactions who were entered into the trial from 1982 to 1985.

interventionPatients were randomly assigned 90 days after transplantation to receive either placebo (260 patients) or low-dose prednisone (263 patients).

main outcome measuresGraft and patient survival. MAIN

resultsAfter at least 5 years of follow-up 50 patients assigned placebo had lost their graft and 17 had died; the corresponding figures for those assigned prednisone were 38 and 16. After an average interval of 1.4 years 143 patients in the placebo group and 123 patients in the prednisone group had stopped therapy with the test drug or had had their treatment group decoded or both. Patients were withdrawn from the study 2 years after stopping the test therapy. The actuarial 5-year graft survival rates were 73% and 85% in the placebo and prednisone groups respectively (p = 0.03), and the actuarial 5-year patient survival rates were 92% and 94% respectively (p = 0.6). This analysis included 43 and 29 graft losses and 14 and 12 deaths in the placebo and prednisone groups respectively. Weibull parametric modelling of graft survival identified the following variables as risk factors for graft loss: histocompatibility leukocyte antigen B (HLA-B) mismatching (p = 0.007), donor death from cerebrovascular accident (p = 0.01), increased donor age (p = 0.02) and being a male recipient (p = 0.05). When these factors were included in the Cox proportional hazards model, the influence of assigned treatment on graft survival was reduced to p = 0.1. Donor death from cerebrovascular accident (p = 0.002), diabetes mellitus in the recipient (p = 0.02) and increased recipient age (p = 0.05) were risk factors for patient death. Renal function and incidence of complications were similar in the treatment groups.

conclusionsContinued administration of low-dose prednisone on alternate days is advisable, particularly in patients with cadaveric grafts and those with previously failed transplants.

Indexed as

AdultAge FactorsCreatinineCyclosporineDouble-Blind MethodDrug Therapy, CombinationFemaleGraft SurvivalHumansKidney Function TestsKidney TransplantationMalePrednisoneRisk FactorsSurvival RateTissue DonorsCreatinineCyclosporinePrednisone

Identifiers

PMID1521210
PMCPMC1336386
OpenAlexW1796019961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.